Bupropion hydrochloride

Description

Bupropion Hydrochloride Extended-release Tablets USP (XL) are formulated to contain 300 mg of bupropion hydrochloride per tablet. Each bottle contains 500 tablets. This medication is available by prescription only and is indicated for specific therapeutic uses as determined by a healthcare professional. The extended-release formulation allows for a gradual release of the active ingredient, facilitating improved patient adherence to the prescribed dosing regimen.

Uses and Indications

Bupropion Hydrochloride Extended-release Tablets USP (XL) are indicated for the treatment of major depressive disorder (MDD) in adults. Additionally, this medication is indicated for the prevention of seasonal affective disorder (SAD).

There are no specific teratogenic or nonteratogenic effects associated with the use of Bupropion Hydrochloride Extended-release Tablets as noted in the available data.

Dosage and Administration

Bupropion Hydrochloride Extended-release Tablets (XL) are available in two strengths: 150 mg and 300 mg, both of which are administered orally.

For the initiation of therapy, the recommended starting dose is 150 mg once daily. After a minimum of 4 days, the dose may be increased to 300 mg once daily, based on clinical response and tolerability. It is important to administer the tablets in the morning to minimize the risk of insomnia.

The maximum recommended dose should not exceed 300 mg per day. Bupropion Hydrochloride Extended-release Tablets should be taken whole and not crushed, chewed, or divided to ensure proper release of the medication.

Healthcare professionals should monitor patients for any adverse effects and adjust the dosage as necessary, considering individual patient factors and response to treatment.

Contraindications

Bupropion is contraindicated in the following situations:

Patients with a seizure disorder should not use bupropion due to the increased risk of seizures. Additionally, bupropion is contraindicated in individuals with a history of eating disorders, such as anorexia nervosa or bulimia, as it may exacerbate these conditions. The use of bupropion is also contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives, including benzodiazepines, due to the potential for seizure activity. Furthermore, bupropion should not be administered to patients who are hypersensitive to bupropion or any components of the formulation, as this may lead to severe allergic reactions.

Warnings and Precautions

There are currently no specific warnings or general precautions associated with the use of this medication. Additionally, no laboratory tests are required or suggested for safe use. Healthcare professionals should remain vigilant and monitor patients for any unforeseen reactions or complications, although no specific instructions for emergency medical assistance or discontinuation of the medication have been provided. It is essential to maintain open communication with patients regarding their treatment and to encourage them to report any unusual symptoms or concerns.

Side Effects

Patients receiving treatment may experience a range of adverse reactions. A boxed warning highlights an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.

Common adverse reactions reported include insomnia, dry mouth, dizziness, weight loss, increased sweating, agitation, anxiety, nausea, vomiting, constipation, and tremor. These reactions are typically observed in clinical trials and may vary in frequency among participants.

Serious adverse reactions can occur, including seizures, hypertension, allergic reactions (which may include anaphylaxis), and neuropsychiatric events such as depression and suicidal thoughts.

In addition to the aforementioned reactions, there are rare cases of serious skin reactions, including Stevens-Johnson syndrome. Other notable adverse reactions may include visual and hearing disturbances, cardiovascular effects such as palpitations, gastrointestinal disturbances like diarrhea, musculoskeletal pain, fatigue, fever, rash, and an increased risk of bleeding, particularly in patients who are concurrently taking anticoagulants.

Healthcare providers should monitor patients for these adverse reactions and manage them appropriately.

Drug Interactions

Bupropion has several notable drug interactions that may impact patient safety and treatment efficacy.

Pharmacodynamic Interactions Bupropion may increase the risk of seizures in patients who are concurrently taking other medications that lower the seizure threshold. This includes, but is not limited to, antipsychotics, antidepressants, and systemic steroids. Clinicians should exercise caution and consider alternative therapies or closely monitor patients for seizure activity when these medications are used together.

The concomitant use of bupropion with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the potential for serious and possibly fatal reactions. Bupropion should not be administered in combination with MAOIs or within 14 days of discontinuing an MAOI.

Pharmacokinetic Interactions Bupropion may also interfere with the results of certain laboratory tests. Specifically, it can affect thyroid function tests and may alter the detection of certain drugs in urine tests. Healthcare providers should be aware of these potential interactions when interpreting laboratory results and may need to consider alternative testing methods or timing.

In summary, careful consideration of bupropion's interactions with other medications and laboratory tests is essential for optimizing patient care and ensuring safety.

Packaging & NDC

The table below lists all NDC Code configurations of Bupropion, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric use of Bupropion Hydrochloride Extended-Release Tablets has not been established. Safety and effectiveness in pediatric patients, including children and adolescents, have not been determined. Therefore, the use of Bupropion in this population is not recommended.

Geriatric Use

Elderly patients may exhibit increased sensitivity to the side effects of bupropion. Due to the potential for reduced kidney function in this population, dosage adjustments may be necessary to ensure safety and efficacy. It is important to note that the safety and efficacy of bupropion in geriatric patients have not been established in clinical studies. Therefore, healthcare providers should exercise caution when prescribing bupropion to elderly patients, closely monitoring for adverse effects and considering individual patient factors when determining the appropriate dosage.

Pregnancy

Bupropion is contraindicated in pregnancy due to the associated risks to the fetus. The safety of bupropion in pregnant women has not been established, and there is a potential risk to fetal outcomes with its use during this period. Therefore, bupropion should only be administered to pregnant patients if the potential benefits outweigh the potential risks to the fetus. Healthcare professionals are advised to carefully consider these factors when prescribing bupropion to women of childbearing potential.

Lactation

There are no specific warnings or recommendations regarding nursing mothers or lactation in the provided drug insert for Bupropion Hydrochloride Extended-Release Tablets. Therefore, healthcare professionals should consider the absence of data when advising lactating mothers on the use of this medication. It is advisable to monitor breastfed infants for any potential effects, although no specific information is available regarding excretion in breast milk or effects on nursing infants.

Renal Impairment

Renal impairment may affect the pharmacokinetics of bupropion. Dosage adjustments may be necessary for patients with renal impairment, particularly for those with moderate to severe renal impairment. Patients with severe renal impairment, defined as a creatinine clearance of less than 30 mL/min, should be closely monitored. Additionally, renal function tests should be performed periodically in patients with renal impairment to ensure appropriate management and dosing. A reduced dose may be required for these patients to mitigate potential risks associated with altered drug clearance.

Hepatic Impairment

Bupropion is contraindicated in patients with severe hepatic impairment. For patients with moderate hepatic impairment, a reduced dose of bupropion should be considered to mitigate the risk of adverse effects.

Prior to initiating treatment, liver function tests should be performed in patients with hepatic impairment to assess their liver status. Caution is advised when prescribing bupropion to these patients, as there is a potential for increased plasma concentrations, which may elevate the risk of adverse effects. Regular monitoring of liver function may be warranted throughout the treatment course to ensure patient safety.

Overdosage

Overdosage of bupropion can lead to significant adverse effects, primarily characterized by the occurrence of seizures, which are known to be dose-dependent. The maximum recommended daily dose of bupropion is 400 mg. Clinical trials have demonstrated that doses exceeding this threshold are associated with an elevated risk of seizure activity.

Symptoms indicative of bupropion overdosage may manifest as agitation, confusion, hallucinations, and various other central nervous system effects. These symptoms necessitate immediate attention and intervention.

In the event of an overdose, it is crucial to provide supportive care to the patient. Close monitoring for seizures and other potential complications is essential to ensure patient safety and effective management of the situation.

Nonclinical Toxicology

Bupropion has been evaluated in nonclinical studies to assess its potential teratogenic effects. The results indicate that bupropion was not teratogenic in animal studies, as no increase in fetal malformations was observed. However, adverse developmental outcomes were noted at doses that were also associated with maternal toxicity. Specifically, in studies conducted with rats, administration of bupropion during pregnancy resulted in decreased fetal weight and an increased incidence of skeletal variations.

Overall, while bupropion does not exhibit teratogenic effects, the presence of adverse developmental outcomes at doses linked to maternal toxicity warrants consideration in the context of its use during pregnancy.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions associated with the use of bupropion. These include seizures, hypertension, and allergic reactions, such as anaphylaxis. Additional adverse reactions reported include insomnia, dry mouth, nausea, vomiting, and dizziness.

Serious neuropsychiatric events have been documented, including suicidal thoughts and behaviors in patients taking bupropion. There have also been reports of increased blood pressure, particularly in individuals with pre-existing hypertension. Skin reactions, such as rash and urticaria, have been observed.

Patients have reported visual disturbances, including blurred vision and changes in color perception. Instances of hepatotoxicity have been noted, with reports of elevated liver enzymes and, in rare cases, liver failure. Furthermore, withdrawal symptoms, including anxiety and irritability, have been reported upon discontinuation of bupropion.

Patient Counseling

Patients should be advised to take Bupropion Hydrochloride Extended-Release Tablets exactly as prescribed by their healthcare provider. It is important to inform patients that Bupropion may increase the risk of seizures, particularly in individuals with a history of seizures or eating disorders.

Patients should be instructed to report any unusual changes in mood or behavior, including any thoughts of self-harm or suicide, to their healthcare provider immediately. Additionally, patients should be advised to avoid alcohol while taking Bupropion, as it may heighten the risk of serious side effects.

It is essential to inform patients that it may take several weeks to experience the full benefits of the medication. Counsel patients to communicate with their healthcare provider if they are pregnant, plan to become pregnant, or are breastfeeding, as this may impact their treatment plan.

Lastly, patients should be advised to keep the medication out of reach of children and to never share their medication with others, emphasizing the importance of using the medication only as directed.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to ensure its stability. Additionally, the product should be discarded after opening to prevent any potential degradation or contamination.

Additional Clinical Information

No further data are available.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Bupropion as submitted by Zydus Lifesciences Limited. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)